Welcome to our dedicated page for Arcturus Therape SEC filings (Ticker: ARCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) files regular reports and current disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed commercial mRNA medicines and vaccines company. On this page, you can review ARCT SEC filings such as annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other documents that detail its financial condition, clinical progress and corporate actions.
Arcturus uses its SEC filings to describe its focus on liver and respiratory rare disease therapeutics and infectious disease vaccines, including RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF) and partnered mRNA vaccine programs for SARS-CoV-2 and influenza. Forms 10-K and 10-Q typically discuss revenue sources from license fees, consulting and technology transfer fees, collaboration payments and grants, as well as research and development and general and administrative expenses tied to programs such as ARCT-032, ARCT-810, KOSTAIVE®, ARCT-2138 and ARCT-2304.
Current reports on Form 8-K provide timely information on material events, including clinical data releases, collaboration developments, regulatory updates for KOSTAIVE and other vaccine candidates, and changes in executive leadership or board composition. Other filings, such as Form 12b-25 notifications, explain any delays in periodic report submissions and confirm expected filing dates.
Stock Titan enhances access to ARCT filings by pairing real-time EDGAR updates with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q reports, as well as notable items in 8-Ks. Users can quickly see disclosures relevant to Arcturus mRNA platforms, collaboration structures, cash position and risk factors, and can also monitor insider-related information when Forms 3, 4 or 5 are available, all in one organized view.
ARK Investment Management LLC and Catherine D. Wood report a 9.19% beneficial stake in Arcturus Therapeutics Holdings Inc. common stock. As of December 31, 2025, they together report ownership of 2,611,099 shares, with ARK holding sole voting and dispositive power over these shares.
Catherine D. Wood reports shared voting and dispositive power over the same 2,611,099 shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcturus. ARK Genomic Revolution ETF is noted as a client with an interest exceeding 5% of the class.
Federated Hermes, Inc. and related reporting persons filed Amendment No. 3 to a Schedule 13G disclosing their beneficial ownership in Arcturus Therapeutics Holdings Inc. common stock. They report beneficial ownership of 3,303,640 shares of common stock, representing 11.63% of the class as of the event date of 12/31/2025. Federated Hermes has sole voting and dispositive power over these shares, while the Voting Shares Irrevocable Trust and Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same amount. The reporting persons state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcturus, and they expressly disclaim beneficial ownership of securities held by managed funds.
Arcturus Therapeutics Holdings Inc. reported that Chief Financial Officer and director Andy Sassine will leave the company under a mutual, amicable separation, with his employment ending on
Under a Separation Agreement, Sassine is entitled to a lump-sum severance equal to 12 months of base salary, bonus eligibility if and when paid to the Chief Executive Officer, reimbursement of certain attorney’s fees, up to 18 months of COBRA premiums, and accelerated vesting plus a 24‑month post‑termination exercise period for his stock options beginning
Arcturus Therapeutics (ARCT) reported Q3 2025 results. Total revenue was $17.2 million, driven by collaboration revenue of $14.2 million (including $13.6 million from CSL Seqirus) and grant revenue of $3.0 million. The company posted a net loss of $13.4 million, or $0.49 per share.
Operating expenses declined as programs matured: research and development fell to $23.3 million and general and administrative to $10.4 million. Cash and cash equivalents were $180.4 million; total cash, cash equivalents and restricted cash were $237.2 million at quarter end. Deferred revenue decreased as COVID-19 vaccine activities transitioned from development to commercial phases under the CSL collaboration.
Regulatory updates were mixed. The European Commission approved KOSTAIVE (ARCT-154) for adults earlier in 2025, while in October the FDA indicated a Biologics License Application for KOSTAIVE would require additional data from a clinical endpoint efficacy study. As of November 5, 2025, 28,412,537 shares of common stock were outstanding.
Arcturus Therapeutics Holdings Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025 and providing a corporate update.
Under Item 2.02, the information is furnished, not filed, and includes forward-looking statements covering programs such as ARCT-032, ARCT-810, and partnered COVID-19 and flu vaccine efforts with CSL Seqirus. The press release is attached as Exhibit 99.1.
Arcturus Therapeutics Holdings Inc. announced on
Arcturus Therapeutics disclosed that Japanese authorities granted manufacturing and marketing approval for a new presentation of KOSTAIVE® (ARCT-2301), its self-amplifying mRNA COVID-19 vaccine targeting the SARS-CoV-2 Omicron sublineage JN.1 variant XEC. The filing notes non-clinical studies showing induction of neutralizing antibodies not only against JN.1 and XEC but also against LP.8.1 and currently circulating variants XFG and NB.1.8.1. The approved formulation is supplied as a two-dose vial with one vial per carton. The company named CSL Seqirus as the partner for distribution and sales in Japan. The disclosure is reported as Regulation FD information in this 8-K.
Arcturus Therapeutics Holdings Inc. (ARCT) reporting person Andy Sassine, who is both a director and the Chief Financial Officer, acquired 1,238 shares of the issuer's common stock on 08/15/2025 through the company's 2020 Employee Stock Purchase Plan (ESPP). The shares were purchased at a price of $16.558 per share, which the filing states equals 85% of the closing price on the purchase date. Following the transaction, the reporting person beneficially owned 221,764 shares. The Form 4/A is an amendment to an earlier filing and is signed by an attorney-in-fact on 08/20/2025. The document contains an explanation that the purchase was effected under the ESPP and the discounted purchase price formula.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
